W



# **INTERNATIONAL SEARCH REPORT**

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference SCB/50965001		of Transmittal of International Search Report 220) as well as, where applicable, item 5 below.
International application No.	International filing date (day/month/year)	(Earliest) Priority Date (day/month/year)
PCT/GB 99/02241	14/07/1999	14/07/1998
Applicant		
JANSSEN PHARMACEUTICA N.V.	. et al.	
This International Search Report has beer according to Article 18. A copy is being tra	n prepared by this International Searching Autl ansmitted to the International Bureau.	hority and is transmitted to the applicant
This International Search Report consists  It is also accompanied by	of a total of <u>6</u> sheets. a copy of each prior art document cited in this	report.
1. Basis of the report		-
<ul> <li>With regard to the language, the including language in which it was filed, unloading to the language.</li> </ul>	international search was carried out on the bar ess otherwise indicated under this item.	sis of the international application in the
the international search w Authority (Rule 23.1(b)).	as carried out on the basis of a translation of the	he international application furnished to this
was carried out on the basis of the	e sequence listing :	nternational application, the international search
<b>                                      </b>	nal application in written form.	_
<del></del>	mational application in computer readable for	n.
	this Authority in written form. this Authority in computer readble form.	
X the statement that the sub	psequently furnished written sequence listing d s filed has been furnished.	loes not go beyond the disclosure in the
		s identical to the written sequence listing has been
2. X Certain claims were four	nd unsearchable (See Box I).	
3. X Unity of invention is lack	ding (see Box II).	
4. With regard to the title,		
X the text is approved as sub	bmitted by the applicant.	
the text has been establish	hed by this Authority to read as follows:	
5. With regard to the abstract,	b. 24 - Lb., Abr. and B	
the text is approved as sub the text has been establish within one month from the	omitted by the applicant. ned, according to Rule 38.2(b), by this Authorit date of mailing of this international search rep	ty as it appears in Box III. The applicant may, port, submit comments to this Authority.
6. The figure of the <b>drawings</b> to be publis		
as suggested by the applic	eant.	X None of the figures.
because the applicant fails	ed to suggest a figure.	<del></del>
because the applicant talk	33	



PCT/GB 99/ 02241

International Application No. PCT/ GB 99/02241

### FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box 3.

Claims Nos.: 30-33,37-40,45-48

Claims 30-33, 37-40 and 45-48 refer to agonists and antagonists of the NAALADases claimed without giving a true technical characterization. Moreover, no such compounds are defined in the application. In consequence, the scope of said claims is ambiguous and vague, and their subject-matter is not sufficiently disclosed and supported (Art. 5 and 6 PCT). No search can be carried out for such purely speculative claims whose wording is, in fact, a mere recitation of the results to be achieved.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

1. Claims: (1-4,10,11) - completely; (9,18-48) - partially

A cDNA molecule encoding a human NAALADase-L protein or a functional equivalent, derivative or bioprecursor thereof.

Corresponding coding sequences, vectors, recombinant host cells, therapeutic and pharmaceutical applications thereof, use in methods to identify agonists and antagonists, agonists and antagonists, use in enzymologic methods.

- 2. Claims: (5,6,12-14) completely; (9,18-48) partially Idem as subject-matter 1 but limited to NAALADase II
- 3. Claims: (7,8,15-17) completely; (9,18-48) partially Idem as subject-matter 1 but limited to NAALADase IV
- 4. Claims: (41,43) partially

As far as not covered by inventions 1-3:

A method for quantifying enzyme activity which comprises contacting an enzyme of interest with a radiolabelled hydrolysable substrate thereof in the presence of scintillation proximity assay beads (SPA).

Said method, wherein said substrate is 3H-NAAG and said enzyme comprises a NAALADase.

5. Claims: (42,43) - partially

As far as not covered by inventions 1-3:

A method of identifying a compound which is an inhibitor or an enhancer of activity of an enzyme, comprising contacting an enzyme of interest with a radiolabelled hydrolysable substrate thereof and said compound to be tested in the presence of scintillation proximity assay beads (SPA), stopping the reaction by adding glycine buffer, and monitoring the signal from the substrate bound to said beads compared to a control.

Said method, wherein said substrate is 3H-NAAG and said enzyme comprises a NAALADase.

## INTERNATIONAL SEARCH REPORT





A. CLASSIFICATION OF SUBJECT MATTER I PC 7 C12N15/52 C12N5/10

A61K31/70 A61K38/43

C12N9/64 A01K67/027 C12Q1/37 G01N33/50 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

#### **B. FIELDS SEARCHED**

 $\begin{array}{ll} \mbox{Minimum documentation searched} & \mbox{(classification system followed by classification symbols)} \\ IPC 7 & C12N & C12Q & A61K & G01N \end{array}$ 

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)


ENTS CONSIDERED TO BE RELEVANT	
Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
SHNEIDER B.L. ET AL.: "Cloning and characterization of a novel peptidase from rat and human ileum."  J. BIOL. CHEM., vol. 272, no. 49, 5 December 1997 (1997-12-05), pages 31006-31015, XP002129302 cited in the application the whole document	1-4, 9-11, 18-29, 34-36, 41-44
LUTHI-CARTER R. ET AL.: "Isolation and characterization of a rat brain cDNA encoding glutamante carboxypeptidase II" PROC. NATL. ACAD. SCI. USA, vol. 95, March 1998 (1998-03), pages 3215-3220, XP002129303 cited in the application the whole document	1-4, 9-11, 18-29, 34-36, 41-44
	SHNEIDER B.L. ET AL.: "Cloning and characterization of a novel peptidase from rat and human ileum."  J. BIOL. CHEM., vol. 272, no. 49, 5 December 1997 (1997-12-05), pages 31006-31015, XP002129302 cited in the application the whole document  LUTHI-CARTER R. ET AL.: "Isolation and characterization of a rat brain cDNA encoding glutamante carboxypeptidase II" PROC. NATL. ACAD. SCI. USA, vol. 95, March 1998 (1998-03), pages 3215-3220, XP002129303 cited in the application

Further documents are listed in the continuation of box C.	X Patent family members are listed in annex.
Special categories of cited documents:      "A" document defining the general state of the art which is not considered to be of particular relevance      "E" earlier document but published on or after the international filing date  "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  "O" document referring to an oral disclosure, use, exhibition or other means  "P" document published prior to the international filing date but later than the priority date claimed	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone  *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.  *&* document member of the same patent family
Date of the actual completion of the international search	Date of mailing of the international search report
31 January 2000	1 1. 05. 2000
Name and mailing address of the ISA  European Patent Office, P.B. 5818 Patentlaan 2  NL - 2280 HV Rijswijk  Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  Fax: (+31-70) 340-3016	Authorized officer  Galli, I

1

# INTERNATIONAL SEARCH REPORT





		/GB 99/02241
C.(Continua	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	CARTER R.E. ET AL.: "Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase." PROC. NATL. ACAD. SCI. USA, vol. 93, January 1996 (1996-01), pages 749-753, XP002129304 cited in the application the whole document	1-4, 9-11, 18-29, 34-36, 41-44
Α	WO 96 15258 A (UPJOHN CO ;ELHAMMER AKE P (US)) 23 May 1996 (1996-05-23) abstract	41-44
P,X	PANGALOS M.N. ETAL.: "Isolation and expression of novel human glutamate carboxypeptidases with N-acetylated alpha-linked acidic dipeptidase and dipeptidyl peptidase IV activity."  J. BIOL. CHEM., vol. 274, no. 13, 26 March 1999 (1999-03-26), pages 8470-8483, XP002129305 the whole document	1-4, 9-11, 18-29, 34-36, 41-44
:		

1

# INTERNATIONAL SEARCH REPORT

Infor

on patent family members

Internationa	Application No	
/GB	99/02241	

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9615258 A	23-05-1996	US 5861318 A AT 191012 T AU 4278196 A DE 69515901 D EP 0792373 A JP 10508749 T	19-01-1999 15-04-2000 06-06-1996 27-04-2000 03-09-1997 02-09-1998